Iris Melanoma

15 registered clinical trials studyying Iris Melanoma.

Status	Trial	Sponsor	Phase
Completed	Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma NCT05628883	H. Lee Moffitt Cancer Center and Research Institute	Phase 1
Active Not Recruiting	Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma NCT02068586	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	Phase 2
Terminated	Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or Decisio NCT02336763	Jonsson Comprehensive Cancer Center	N/A
Terminated	Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases NCT01730157	Case Comprehensive Cancer Center	EARLY_Phase 1
Completed	Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye NCT01413191	National Cancer Institute (NCI)	Phase 2
Completed	Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye NCT00329641	National Cancer Institute (NCI)	Phase 2
Completed	Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye NCT01143402	National Cancer Institute (NCI)	Phase 2
Completed	Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic I NCT01100528	Case Comprehensive Cancer Center	Phase 2
Completed	VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00450255	National Cancer Institute (NCI)	Phase 2
Completed	AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma NCT00243061	National Cancer Institute (NCI)	Phase 2
Completed	Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma NCT00288041	National Cancer Institute (NCI)	Phase 2
Completed	Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma NCT00121225	National Cancer Institute (NCI)	Phase 2
Completed	Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma NCT00089063	National Cancer Institute (NCI)	Phase 2
Completed	Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma NCT00085189	University of Southern California	Phase 2
Completed	Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patient NCT01989572	National Cancer Institute (NCI)	Phase 3